Amgen Inc. (AMGN) Stock Soars 8.86% to Monthly High on Strong Q3 Earnings, Portfolio Expansion

The share price rose to its highest level so far this month today, with an intraday gain of 8.86%.

Amgen Inc. (AMGN) has surged on robust financial results and a strengthened product portfolio. The biotechnology leader reported a 12.4% year-on-year revenue increase to $9.56 billion in Q3 2025, exceeding analyst estimates, while raising full-year revenue guidance to $36.2 billion. Adjusted earnings per share hit $5.64, outpacing expectations by 12.5%, driven by a 26.4% operating margin and strong demand for key products like Prolia, Repatha, and Tepezza. Strategic acquisitions, including Horizon Therapeutics, have expanded its rare-disease offerings, bolstering long-term growth prospects. Institutional investors have also increased stakes in the stock, reflecting confidence in its 3.2% dividend yield and financial resilience.

Despite these positives, risks linger. Amgen faces hedging losses from foreign currency contracts and potential regulatory challenges, as highlighted in its 10-Q filing. Analysts project modest 1.1% revenue growth over the next 12 months, with a mixed "Hold" average rating and a $300.94 price target. However, the company’s elevated guidance and operating margins suggest it remains well-positioned to navigate market uncertainties. The recent rally, fueled by earnings strength and strategic momentum, underscores investor optimism, though macroeconomic and regulatory headwinds warrant caution.